Delayed Kidney Response in AL Amyloidosis: prevalence and clinical significance
Clicks: 1
ID: 323767
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
1 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #123 of 125 articles by views in clinical kidney journal
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 125 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract Introduction Kidney involvement is frequent in AL amyloidosis and significantly impacts prognosis. Although hematologic response is the recommended marker for monitoring treatment efficacy, organ-specific responses are frequently evaluated in clinical practice. In this context, the significance and optimal timing of kidney-specific response remain poorly defined in the literature. Methods We conducted a retrospective study of patients with renal AL amyloidosis treated with or without anti-clonal therapy (ACT). Kidney response rates and their timing were analyzed. Patients were stratified by time to kidney response: very early (0–6 months), early (6–12 months), and late (>12 months). Baseline characteristics, treatments, and outcomes were compared across groups. Results Seventy-six patients were included; 58 received ACT. Among them, 59% achieved hematologic response and 52% achieved kidney response. Kidney response was associated with improved kidney survival. Median time to hematologic response was 4.58 (1–9.38) months, whereas median time to partial and complete kidney response were 9 (6–18) and 16.5 (9–25) months (p = 0.03). Kidney outcomes were similar regardless of response timing. Patients with late kidney response had longer time to hematologic response (9.75 vs. 3 months, p = 0.02), longer treatment duration (24.5 vs. 9 months, p = 0.02), and received more ACT lines, particularly among those with very early hematologic response. Conclusion Kidney response in AL amyloidosis occurs later than hematologic response but is associated with favorable kidney outcomes. In our study, delayed kidney response was associated with longer treatment duration despite hematologic response. Prospective studies are needed to determine whether treatment decisions based on kidney response alone improve or worsen patient outcomes.
| Reference Key |
openalex_W7172534571
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Irene Martín Capón, Andrea Cifuentes, José Enrique Ruiz-Cabello, Teresa Cavero, Pilar Auñón, Marina Alonso, Fernando Caravaca‐Fontán, Eduardo Gutierrez, Manuel Praga, Enrique Morales, Ángel M. Sevillano |
| Journal | clinical kidney journal |
| Year | 2026 |
| DOI |
10.1093/ckj/sfag241
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.